Literature DB >> 25252194

Dynamics of pneumococcal carriage among day-care center attendees during the transition from the 7-valent to the higher-valent pneumococcal conjugate vaccines in Greece.

Ioanna N Grivea1, Kostas N Priftis2, Apostolos Giotas2, Doxa Kotzia2, Alexandra G Tsantouli1, Konstantinos Douros2, Aspasia N Michoula1, George A Syrogiannopoulos3.   

Abstract

BACKGROUND: In Greece recently, higher-valent pneumococcal conjugate vaccines (PCVs) replaced the 7-valent (PCV7); the 10-valent (PCV10) became available in May 2009 and the 13-valent (PCV13) in June 2010.
METHODS: We investigated the nasopharyngeal colonization with Streptococcus pneumoniae in day-care center attendees in Athens and the prefecture of Viotia. Between December 2010 and June 2011, nasopharyngeal cultures were obtained 4 times, at enrollment and then every 6 to 8 weeks.
RESULTS: Among the 233 children, 225 (96.6%) had been vaccinated with ≥1 dose of PCV7. One tenth of the PCV7 vaccinated attendees had also received ≥1 dose of PCV13 or PCV10. During the 4 samplings, 358 isolates were recovered from a total of 874 samples. Of the 233 children, 183 (78.5%) were found to carry S. pneumoniae at least once. The overall serotype distribution among carriers was similar regardless of the time lapsed since the last PCV7 dose. A high frequency of 19A (17.1%) coincided with a low frequency of 19F (1.4%). Non-PCV13 serotypes accounted for 73.1% of the isolates; 23B, 15B/C, 16F, 21, 11A, 15A, 6C, 10A, 22F and 23A were the most common. Among attendees aged 24-59 months (median age 42 months), prolonged carriage of a non-PCV13 serotype was relatively common, mainly for 21 and 16F. One out of 4 cases of colonization with the prevalent non-PCV13 serotypes was followed by persistent carriage for 5 to 14 weeks.
CONCLUSIONS: During this period of transition to the higher-valent PCVs in the day-care center setting, non-PCV13 serotypes dominated and exhibited prolonged colonization. The frequency and the duration of prolonged carriage tends to be increased, if sampling frequency increases and the carriage time before and after positive cultures is taken into consideration. Further studies regarding the fitness of the colonizing non-PCV13 serotypes will likely to be seen in the future.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  10-Valent pneumococcal conjugate vaccine; 13-Valent pneumococcal conjugate vaccine; 7-Valent pneumococcal conjugate vaccine; Day-care centers; Nasopharyngeal carriage; Streptococcus pneumoniae

Mesh:

Substances:

Year:  2014        PMID: 25252194     DOI: 10.1016/j.vaccine.2014.09.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  A cross-sectional vaccination coverage study in preschool children attending nurseries-kindergartens: Implications on economic crisis effect.

Authors:  Theano Georgakopoulou; Damianos Menegas; Antonis Katsioulis; Maria Theodoridou; Jenny Kremastinou; Christos Hadjichristodoulou
Journal:  Hum Vaccin Immunother       Date:  2017-01-02       Impact factor: 3.452

2.  Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world.

Authors:  Yadong A Cui; Harshila Patel; William M O'Neil; Se Li; Patricia Saddier
Journal:  Hum Vaccin Immunother       Date:  2017-01-26       Impact factor: 3.452

3.  Impact of Pneumococcal Vaccination on Nasopharyngeal Carriage of Streptococcus pneumoniae and Microbiota Profiles in Preschool Children in South East Poland.

Authors:  Karolina Kielbik; Aleksandra Pietras; Joanna Jablonska; Adrian Bakiera; Anna Borek; Grazyna Niedzielska; Michal Grzegorczyk; Ewelina Grywalska; Izabela Korona-Glowniak
Journal:  Vaccines (Basel)       Date:  2022-05-17

4.  Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era.

Authors:  Mark van der Linden; Stephanie Perniciaro; Matthias Imöhl
Journal:  BMC Infect Dis       Date:  2015-05-05       Impact factor: 3.090

5.  Determinants of vaccination coverage and adherence to the Greek national immunization program among infants aged 2-24 months at the beginning of the economic crisis (2009-2011).

Authors:  Papaevangelou Vassiliki; Koutsoumbari Ioanna; Vintila Artemis; Klinaki Eleni; Zellos Aglaia; Achilleas Attilakos; Tsolia Maria; Kafetzis Dimitris
Journal:  BMC Public Health       Date:  2014-11-20       Impact factor: 3.295

6.  Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern Japan.

Authors:  M Kawaguchiya; N Urushibara; M S Aung; S Morimoto; M Ito; K Kudo; A Sumi; N Kobayashi
Journal:  New Microbes New Infect       Date:  2015-11-11

Review 7.  A reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009-2016).

Authors:  Marta Moreira; Olga Castro; Melissa Palmieri; Sofia Efklidou; Stefano Castagna; Bernard Hoet
Journal:  Hum Vaccin Immunother       Date:  2016-12-20       Impact factor: 3.452

8.  Aboriginal and non-Aboriginal children in Western Australia carry different serotypes of pneumococci with different antimicrobial susceptibility profiles.

Authors:  Eileen M Dunne; Kylie Carville; Thomas V Riley; Jacinta Bowman; Amanda J Leach; Allan W Cripps; Denise Murphy; Peter Jacoby; Deborah Lehmann
Journal:  Pneumonia (Nathan)       Date:  2016-09-05

9.  Pneumococcal Nasopharyngeal Carriage in Young Healthy Children After Pneumococcal Conjugate Vaccine in Turkey.

Authors:  Ahmet Arvas; Haluk Çokuğraş; Emel Gür; Nevriye Gönüllü; Zeynep Taner; Hrisi Bahar Tokman
Journal:  Balkan Med J       Date:  2017-08-04       Impact factor: 2.021

10.  Molecular surveillance of pneumococcal carriage following completion of immunization with the 13-valent pneumococcal conjugate vaccine administered in a 3 + 1 schedule.

Authors:  George A Syrogiannopoulos; Ioanna N Grivea; Maria Moriondo; Francesco Nieddu; Aspasia N Michoula; Maria Rita Calabrese; Michael Anthracopoulos; Chiara Azzari
Journal:  Sci Rep       Date:  2021-12-30       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.